Evidence map›Paper›PMID 12098721›Full record

Trial reportBMJ (Clinical research ed.)2002

Vitamin E supplementation and macular degeneration: randomised controlled trial.

Hugh R Taylor, Gabriella Tikellis, Luba D Robman, Catherine A McCarty, John J McNeil

Abstract readClinical TrialRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BMJ (Clinical research ed.), 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Hugh R TaylorCentre for Eye Research Australia, University of Melbourne, Locked Bag 8, East Melbourne, Victoria, Australia, 8002. h.taylor@unimelb.edu.au
Gabriella Tikellis
Luba D Robman
Catherine A McCarty
John J McNeil

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo determine whether vitamin E supplementation influences the incidence or rate of progression of age related maculopathy (AMD).

designProspective randomised placebo controlled clinical trial.

settingAn urban study centre in a residential area supervised by university research staff.

participants1193 healthy volunteers aged between 55 and 80 years; 73% completed the trial on full protocol.

interventionsVitamin E 500 IU or placebo daily for four years.

main outcome measuresPRIMARY OUTCOME: development of early age related macular degeneration in retinal photographs. Other measures included alternative definitions of age related macular degeneration, progression, changes in component features, visual acuity, and visual function

resultsThe incidence of early age related macular degeneration (early AMD 3) was 8.6% in those receiving vitamin E versus 8.1% in those on placebo (relative risk 1.05, 95% confidence interval 0.69 to 1.61). For late disease the incidence was 0.8% versus 0.6% (1.36, 0.67 to 2.77). Further analysis showed no consistent differences in secondary outcomes.

conclusionDaily supplement with vitamin E supplement does not prevent the development or progression of early or later stages of age related macular degeneration.

Indexed as

AgedAged, 80 and overAntioxidantsDisease ProgressionFollow-Up StudiesHumansIncidenceMacular DegenerationMiddle AgedPrevalenceProspective StudiesVictoriaVitamin EAntioxidantsVitamin E

Identifiers

PMID12098721
PMCPMC116664

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.